Jörge E. Cortes
Impact in
- Hematology top 0.01%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Genetics top 0.01%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 1.8k
- Chronic Myeloid Leukemia Treatments 1.2k
- Acute Myeloid Leukemia Research 759
- Multiple Myeloma Research and Treatments 88
- Genetics 1.1k
- Chronic Lymphocytic Leukemia Research 852
- Myeloproliferative Neoplasms: Diagnosis and Treatment 279
- Co-authors
- Hagop Kantarjian (251 shared papers)Susan Mary O'Brien (251 shared papers)Guillermo Garcia‐Manero (251 shared papers)Francis Joseph Giles (251 shared papers)Farhad Ravandi (251 shared papers)Elias Joseph Jabbour (251 shared papers)Deborah Ann Thomas (251 shared papers)Stefan H Faderl (251 shared papers)
- Journals
- Blood (893 papers)Cancer (216 papers)Leukemia (80 papers)American Journal of Hematology (78 papers)Journal of Clinical Oncology (64 papers)
- Partner nations
- United StatesGermanyItaly
In The Last Decade
Jörge E. Cortes
2.1k papers receiving 113.6k citations
Jörge E. Cortes's Hit Papers
Peers
Comparison fields: 5 of 192
- Hematology 80.2k
- Genetics 46.8k
- Rheumatology 21.1k
- Oncology 17.3k
- Public Health, Environmental and Occupational Health 17.3k
Countries citing papers authored by Jörge E. Cortes
This map shows the geographic impact of Jörge E. Cortes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jörge E. Cortes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jörge E. Cortes more than expected).
Fields of papers citing papers by Jörge E. Cortes
This network shows the impact of papers produced by Jörge E. Cortes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jörge E. Cortes. The network helps show where Jörge E. Cortes may publish in the future.
Co-authors
The 25 scholars most cited alongside Jörge E. Cortes, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 2.2k papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data Hit paper breakdown → | 2022 | 1856 |
| 2 | European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 Hit paper breakdown → | 2013 | 1614 |
| 3 | Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias Hit paper breakdown → | 2006 | 1437 |
| 4 | A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome Hit paper breakdown → | 2003 | 1347 |
| 5 | Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Hit paper breakdown → | 2010 | 1290 |
| 6 | Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL Hit paper breakdown → | 2006 | 1087 |
| 7 | European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia Hit paper breakdown → | 2020 | 1080 |
| 8 | Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet Hit paper breakdown → | 2009 | 1050 |
| 9 | Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis Hit paper breakdown → | 2010 | 992 |
| 10 | Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML Hit paper breakdown → | 2019 | 980 |
| 11 | A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias Hit paper breakdown → | 2013 | 940 |
| 12 | CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia Hit paper breakdown → | 2018 | 791 |
| 13 | Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia Hit paper breakdown → | 2005 | 781 |
| 14 | Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial Hit paper breakdown → | 2016 | 756 |
| 15 | Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies Hit paper breakdown → | 2003 | 702 |
| 16 | Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia Hit paper breakdown → | 2000 | 677 |
| 17 | Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity Hit paper breakdown → | 2010 | 652 |
| 18 | Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias Hit paper breakdown → | 2012 | 622 |
| 19 | Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia Hit paper breakdown → | 2013 | 608 |
| 20 | Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents Hit paper breakdown → | 2013 | 604 |
About Jörge E. Cortes
Jörge E. Cortes is a scholar working on Hematology, Genetics, Rheumatology, Public Health, Environmental and Occupational Health and Oncology, having authored 2.2k papers that have together received 117.0k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (1.2k papers), Chronic Lymphocytic Leukemia Research (852 papers), Acute Myeloid Leukemia Research (759 papers), Eosinophilic Disorders and Syndromes (428 papers), Acute Lymphoblastic Leukemia research (362 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (279 papers), Lymphoma Diagnosis and Treatment (105 papers) and Multiple Myeloma Research and Treatments (88 papers). The work is most often cited by research in Hematology (80.2k citations), Genetics (46.8k citations), Rheumatology (21.1k citations), Oncology (17.3k citations) and Public Health, Environmental and Occupational Health (17.3k citations). Jörge E. Cortes has collaborated with scholars based in United States, Germany and Italy. Frequent co-authors include Hagop Kantarjian, Susan Mary O'Brien, Guillermo Garcia‐Manero, Francis Joseph Giles, Farhad Ravandi, Elias Joseph Jabbour, Deborah Ann Thomas, Stefan H Faderl, Srđan Verstovšek and Alfonso Quintás‐Cardama. Their work appears in journals such as Blood, Cancer, Leukemia, American Journal of Hematology and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.